Study Shows Donor Hepatitis C Positivity Does Not Harm Renal Transplant Recipients

Researchers have released a groundbreaking study indicating that donor positivity for hepatitis C virus (HCV) does not lead to worse rejection rates or mortality outcomes in patients who do not have HCV. This finding opens up a new avenue for expanding the pool of available kidneys for transplant.

Key Study Findings

A recent retrospective, propensity score-matched case-control study analyzed data from the TriNetX US Collaborative Network. The study explored the impact of donor HCV status on post-transplant outcomes in HCV-negative recipients.

Participant Details

The study included 453 patients who received kidneys from HCV-positive donors and 23,818 patients who received kidneys from HCV-negative donors. After matching for various risk factors, each group consisted of 450 patients.

Primary and Secondary Outcomes

The primary outcome measured was the incidence of graft rejection within one year post-transplant. Secondary outcomes included kidney function, non-HCV infections, and the efficacy of direct-acting antiviral (DAA) treatments.

Results Reveal Positive Outcomes

The study found that the incidence of graft rejection in the HCV-positive donor group (22.8%) was not significantly higher than that in the HCV-negative donor group (16.6%). When cases of delayed graft function were excluded, the difference in rejection rates became negligible (19.2% vs. 16.3%).

Mortality rates at one year were similar in both groups (7.4% and 6.54%, respectively). Mean estimated glomerular filtration rate (eGFR) did not significantly differ between the groups at one year post-transplant.

Addressing Concerns About Non-HCV Infections

The study did not find significant differences in incidences of Epstein-Barr virus (EBV), cytomegalovirus (CMV), or BK virus viremia between the two groups. This suggests that receiving an HCV-positive donor kidney does not disproportionately increase the risk of acquiring other viral infections.

The Role of Direct-Acting Antivirals

Among recipients of HCV-positive donor kidneys, the most commonly used DAA regimen was glecaprevir/pibrentasvir. The majority of these patients (94.65%) achieved a sustained virologic response 12 weeks after DAA therapy.

Implications for Transplantation

These findings provide strong support for the use of kidneys from HCV-positive donors in patients who do not have HCV, thereby increasing the availability of transplantable organs. This approach could significantly alleviate the shortage of donor organs, which poses a critical challenge in modern transplant medicine.

Expert Commentary

According to Michael Kueht, MD, the lead investigator of the study, “Although the use of allografts from HCV-positive donors is increasing, concerns about post-transplant outcomes often discourage their use. These data support the expansion of the donor pool by utilizing organs from HCV-positive donors for HCV-negative recipients.”

Conclusion

This study marks an important step forward in addressing the critical shortage of donor kidneys. By demonstrating that using kidneys from HCV-positive donors does not lead to worse outcomes for HCV-negative recipients, it paves the way for a wider adoption of this practice. This could ultimately improve the lives of many patients with end-stage renal disease.

We invite our readers to share their thoughts on this groundbreaking research. If you have any questions or comments, please feel free to leave them below. Also, don’t forget to subscribe to Archynetys for more informative and medically relevant news.